INFORMATION ABOUT
Prescribing BUCCOLAM (Midazolam)

How To Prescribe BUCCOLAM (Midazolam)

Midazolam is a Schedule 3 Controlled Drug. This means when writing a prescription for BUCCOLAM there are specific prescription requirements. All prescriptions for Controlled Drugs that are subject to the prescription requirements must always state:1
  • The patient’s title, forename, surname, address and age
  • The name and form of the drug, strength of the preparation, and dose to be taken
  • The total quantity to be dispensed (or number of dose units e.g. 10mg/2mL x 4 syringes) must be written in both letters and numerals
  • The prescriber’s signature must be handwritten (Advanced electronic signatures can be accepted for Schedule 3 Controlled Drugs where the Electronic Prescribing Service (EPS) is used)
  • The prescription is only valid for 28 days after the appropriate date

A prescription for BUCCOLAM should be written as per the following examples*:

  • Buccolam 2.5mg/0.5mL oromucosal solution pre-filled syringes,
    4 unit dose, one as directed
  • Buccolam 5mg/1mL oromucosal solution pre-filled syringes,
    4 unit dose, one as directed
  • Buccolam 7.5mg/1.5mL oromucosal solution pre-filled syringes,
    4 unit dose, one as directed
  • Buccolam 10mg/2mL oromucosal solution pre-filled syringes,
    4 unit dose, one as directed

*BUCCOLAM is indicated for:

The treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to <18 years).

BUCCOLAM must only be used by parents/carers where the patient has been diagnosed to have epilepsy. For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.2

Government Help With Prescription And Other Health Costs

The total annual cost of established epilepsy to the UK was estimated at £1930 million, over 69% of which was due to indirect costs (unemployment and excess mortality).3

The BUCCOLAM Patient Website details the government provisions which are available to help patients and their carers; click here to access this resource. These include Medical Exemption Certificates, prescription prepayment certificates, tax credits, and travel costs reimbursement schemes.

Please note that in order to claim some of these provisions, your patient will need you to complete and sign a Medical Exemption Certificate.4

References:

  1. National Institute for Health and Care Excellence (NICE). Controlled drugs and drug dependence. Available from: https://bnf.nice.org.uk/guidance/controlled-drugs-and-drug-dependence.html 
  2. BUCCOLAM SmPC. Available from: https://www.medicines.org.uk/emc/product/7460 
  3. Welsh Government. Low income scheme: help with NHS health costs. Available from: https://gov.wales/low-income-scheme-help-nhs-health-costs (accessed 04 Dec 2020)
  4. Scottish Government. Help with health costs: information booklet. Available from: https://www.gov.scot/publications/hcs2-booklet-quick-guide-help-health-costs-november-2019/ (accessed 04 Dec 2020)
  5. Nidirect Government Services. Help with health costs. Available from: https://www.nidirect.gov.uk/articles/help-health-costs (accessed 04 Dec 2020)
  6. NHS. Help with health costs. Available from: https://www.nhs.uk/nhs-services/help-with-health-costs/ (accessed 04 Dec 2020)
  7. NHS England. Next Steps on the NHS Five Year Forward View. Available from: https://www.england.nhs.uk/wp-content/uploads/2017/03/NEXT-STEPS-ON-THE-NHS-FIVE-YEAR-FORWARD-VIEW.pdf (accessed 04 Dec 2020)

This information is provided as a resource to HCP’s who prescribe or administer Buccolam.

Reporting of adverse events (Healthcare Professionals in the UK)

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Neuraxpharm. at: pv-uk@neuraxpharm.com